Personnel changes at Evonik: Dr Hans-Josef Ritzert to head the Greater China Region and Dr Jean-Luc Herbeaux the new Health Care Business Line
Dr Hans-Josef Ritzert takes over as head of the Greater China Region
Dr Jean-Luc Herbeaux heads the new Health Care Business Line
Dr. Hans Josef Ritzert, who has headed the Exclusive Synthesis & Pharma Amino Acids Business Line since 2009 and was previously head of the Catalysts Business Line, takes up the position Regional President Greater China of Evonik Industries as of September 1, 2011. In his new function, Ritzert will be responsible for the Evonik business in the strategically important Greater China Region. Evonik has about 3500 employees in the Region and a turnover exceeding €1.0 billion in 2010. Ritzert, who holds a doctorate in chemistry, takes over the position from Dr. Dahai Yu, who was appointed to the Executive Board of Evonik Industries in April 2011.
Dr. Jean-Luc Herbeaux will head the newly formed Health Care Business Line. Herbeaux, who has been heading the Pharma Polymers Business Line of Evonik since the beginning of 2009, joined Evonik Industries (then Degussa) in 2000. A native of France, Herbeaux studied in France and the USA and spent 8 years of his life in Asia, teaching and doing business.
Linked FilesDr Hans-Josef RitzertDr Jean-Luc HerbeauxDr Thomas RiermeierDr Klaus StinglDr Thomas Hermann
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Its activities focus on the key megatrends health and nutrition, resource efficiency and globalization. In 2010 about 80 percent of the Group’s chemicals sales came from activities where it ranks among the market leaders. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around €13.3 billion and an operating profit (EBITDA) of about €2.4 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.